By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:



Company News
Ignyta (RXDX) Reports Granting Of Inducement Awards 9/18/2017 7:33:53 AM
Ignyta (RXDX) Provides Update On Entrectinib And RXDX-105 At The ESMO 2017 Congress 9/11/2017 6:28:35 AM
Ignyta (RXDX) Announces Presentation Of New Phase IB Clinical Data On RXDX-105 In RET Fusion-Positive NSCLC At ESMO 2017 Congress 9/8/2017 7:12:55 AM
Ignyta (RXDX) Provides Regulatory Update On Entrectinib ROS1 Lung Cancer Development Program 9/6/2017 8:43:49 AM
Ignyta (RXDX) To Host Conference Call And Webcast On Entrectinib ROS1 Lung Cancer Update On September 6, 2017 8/31/2017 10:37:38 AM
Ignyta (RXDX) Announces Second Quarter 2017 Company Highlights And Financial Results 8/9/2017 7:40:37 AM
Ignyta (RXDX) Receives FDA Orphan Drug Designation For Entrectinib For Treatment Of NTRK Fusion-Positive Solid Tumors 7/10/2017 6:38:13 AM
Ignyta (RXDX) Granted Breakthrough Therapy Designation For Entrectinib By U.S. FDA 5/15/2017 6:16:42 AM
The FDA Calls Ignyta (RXDX)'s Tumor Drug Entrectinib A Breakthrough 5/15/2017 6:16:08 AM
Ignyta (RXDX) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 5/10/2017 7:38:06 AM